2407860-35-7
2407860-35-7 structure
- Name: ErSO
- Chemical Name: ErSO
- CAS Number: 2407860-35-7
- Molecular Formula: C22H13F6NO3
- Molecular Weight: 453.33
- Catalog: Research Areas Cancer
- Create Date: 2021-09-10 18:49:33
- Modify Date: 2025-08-25 15:05:43
-
ErSO is a selective anticipatory unfolded protein response (a-UPR) activator. ErSO acts through ERα to elicit strong and sustained cytotoxic activation of the a-UPR. ErSO can be used for the research of cancer[1].
| Name | ErSO |
|---|
| Description | ErSO is a selective anticipatory unfolded protein response (a-UPR) activator. ErSO acts through ERα to elicit strong and sustained cytotoxic activation of the a-UPR. ErSO can be used for the research of cancer[1]. |
|---|---|
| Related Catalog | |
| Target |
a-UPR[1] |
| In Vitro | ErSO (1~1000 nM; 24 hours; MCF-7 cells) shows that IC50 value is 20.3 nM in MCF-7 cells and inhibits cell viability[1]. ErSO (1 μM; 24 hours; TYS cells) rapidly kills ERα-positive breast cancer cells. ErSO is effective against both the breast cancer cell lines expressing wild-type ERα and the ERαY537S and ERαD538G mutations such as human breast cancer cell lines TYS and TDG. ErSO is also effective against tamoxifen- and fulvestrant-resistant breast cancer cell lines containing wild-type ERα. ErSO activity is independent of the presence of estrogen. ErSO induces rapid killing of ERα-positive MCF-7 human breast cancer cells[1]. Cell Viability Assay[1] Cell Line: MCF-7 cells Concentration: 1~1000 nM Incubation Time: 24 hours Result: Showed that IC50 value is 20.3 nM in MCF-7 cells and inhibited cell viability. |
| In Vivo | ErSO (10 or 40 mg/kg; p.o.; 21 days) results in elimination of these tumors, with >90% reduction in all cases[1]. ErSO (0.5~40 mg/kg; p.o.; 3 weeks) is sufficient for a robust response[1]. ErSO (10 and 40 mg/kg; p.o.; 14 days) induces >10,000-fold regression of TYS-luciferase-expressing breast tumors in all five mice and >100,000-fold regression (to undetectable amounts) within 14 days as shown by bioluminescent imaging of luciferase as compared to vehicle-treated mice[1]. ErSO (40 mg/kg; i.p.; 14 days) greatly reduces metastatic burden[1]. ErSO treatment ablates mutant ERα breast cancer cell line xenografts and a PDX mouse model[1]. Animal Model: Nu/J mice[1] Dosage: 10 or 40 mg/kg Administration: P.o.; 21 days Result: Resulted in elimination of these tumors, with >90% reduction in all cases. Animal Model: Mice[1] Dosage: 0.5~40 mg/kg Administration: P.o.; 3 weeks Result: Sufficient for a robust response. Animal Model: Mice[1] Dosage: 40 mg/kg Administration: I.p.; 14 days Result: Metastatic burden was greatly reduced |
| References |
| Molecular Formula | C22H13F6NO3 |
|---|---|
| Molecular Weight | 453.33 |